MPH

CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000

Retrieved on: 
Tuesday, April 9, 2024
Xchange, Pharmacology, Health, Mentorship, NYCEDC, Health equity, Research, Female, Doctor of Philosophy, Faculty, NIH, Male, Syneos Health, MPH, Pediatrics, Drug development, Economic development, Cure, Nursing

Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.

Key Points: 
  • Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.
  • The deadline for XSeed Award application submissions is May 31, 2024, and virtual finalist presentations will be June 28, 2024.
  • "Deerfield is pleased to continue our collaboration on the transformational XSeed program, alongside the NYCEDC, Cure and the experts who comprise our enthusiastic XSeed Award Leadership Committee."
  • "We look forward to welcoming the XSeed Award winners who, along with the Cure Xchange Challenge winners, are startups advancing health through collaboration and community building via Cure."

Cathie Biga is New American College of Cardiology President

Retrieved on: 
Monday, April 8, 2024
College, FACC, Culture, Practice management, NCDR, Science, Trustee, Knowledge, History, Registry, Health policy, MSN, American College, MPH, Multimedia, ACC, Health, MSCE, Nursing

ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president. She will serve a one-year term representing over 56,000 cardiovascular care team members around the world and leading the cardiovascular organization in its mission to transform cardiovascular care and improve heart health for all.

Key Points: 
  • ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president.
  • "The concept of 'standing on the shoulders of giants' is often referenced when talking about leadership changes and transformation over time.
  • She's been a member of the ACC Board of Trustees for six years, most recently serving as vice president.
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Monday, April 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Retrieved on: 
Monday, April 8, 2024
Freedom, Atrial fibrillation, Risk, Patient, Stroke, PFA, Medtronic, Femoral vein, Pulse, Heart failure, Ventricular fibrillation, MPH, Index, Heart, Safety, AAD, Annual general meeting, Cardiac tamponade, Pulmonary vein stenosis

DUBLIN and BERLIN, April 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib). Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.

Key Points: 
  • Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.
  • The Sphere-360 catheter was developed with the goal to simplify the atrial fibrillation procedure while enhancing efficiency and providing high durability of lesions.
  • Furthermore, the catheter is fully integrated with the Affera™ Mapping and Ablation System for complete visualization inside the heart and electroanatomical mapping, making it a true all-in-one single-shot catheter for mapping, ablation, and validation.
  • "These results are very encouraging as they show the Sphere-360 catheter has the potential to be an important part of next generation AFib care."

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.

TGH Women's Institute Receives Highest Honor from National Accrediting Body

Retrieved on: 
Friday, April 5, 2024
Hospital, Mother, Midwifery, Tampa General Hospital, Obstetrics, Certification, Chair, Gynaecology, Joint Commission, Health, TGH, Patient, DNP, Accreditation, Infant, Pregnancy, Woman, MPH, Safety, Nursing care plan, Physician, Nursing

TAMPA, Fla., April 5, 2024 /PRNewswire/ -- The Women's Institute at Tampa General Hospital (TGH) announced that it has received the highest national designation (Level IV) in maternal care from The Joint Commission — the gold standard in accreditation — underscoring its commitment to excellence in care for mothers and babies.

Key Points: 
  • The Joint Commission, a nonprofit organization dedicated to empowering health care organizations in providing the highest level of safety and quality, verified the TGH Women's Institute as a Level IV Maternal Care hospital.
  • Founded in 1951, The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care.
  • The TGH Women's Institute provides a full range of women's health services, from routine obstetrics and gynecology to more complex maternal-fetal medicine and neonatal care.
  • The Institute is one of only 11 health care facilities in Florida and the only one in Hillsborough County to receive this distinction.

Foundation for Opioid Response Efforts (FORE) Announces $1.4 Million Grant to Equal Justice Works to Launch National Legal Fellowship Program

Retrieved on: 
Thursday, March 21, 2024
Employment, Legal aid, Organization, Health, Education, Child, Opioid use disorder, Equal Justice Works, Housing, Lawyer, MPH, Opioid, Equal justice under law, Private law, Nursing

New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced it is awarding a grant of $1,361,005 over 30 months to Equal Justice Works to launch a national Opioid Crisis Response Legal Fellowship Program that will address the legal consequences of the opioid crisis.

Key Points: 
  • New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced it is awarding a grant of $1,361,005 over 30 months to Equal Justice Works to launch a national Opioid Crisis Response Legal Fellowship Program that will address the legal consequences of the opioid crisis.
  • “The opioid crisis cannot be fully addressed without multidisciplinary interventions, including legal assistance,” said Karen A. Scott, MD., MPH, President of FORE.
  • “We thank the Foundation for Opioid Response Efforts for their generous grant,” said Verna Williams, CEO of Equal Justice Works.
  • “FORE’s support will mobilize six Equal Justice Works Fellows to address critical legal needs frequently arising from opioid use disorder, such as child custody matters, housing, healthcare, and employment.

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

Retrieved on: 
Wednesday, March 20, 2024
Tendinopathy, Artificiality, Health, Patient, Conditional sentence, History, Artificial intelligence, Lantern, Mantle cell lymphoma, OTCQX, Microsoft HoloLens, Context, Corporation, NEO, Microsoft, Automation, MCL, DHL, Splenic infarction, Diabetes, Risk, PALM, Radiology, Software, Treatment, UiPath, OTCQB, Strategic alliance, Prevalence, Disease, Microsoft Mesh, Hospital, Research, News, WELL, Student, TSX, MPH, Nursing, Machine learning, Diagnosis, TED (conference), OSCE, Growth, Cancer, Trust, Sarcoma, NHL, Appendicitis, Ecosystem, Probability, AIDX, Medical device

A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.
  • MarketsAndMarkets continued: “Based on component, the AI in medical diagnostics market is bifurcated into software, services, and hardware.
  • The software segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.
  • The hospitals segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.

Treatment AI Passes Medical School Clinical Exam with 92% Success Rate

Retrieved on: 
Wednesday, March 20, 2024
Medical education, Tendinopathy, School, OSCE, Disease, Health, Cancer, Splenic infarction, Diabetes, Patient, History, AI, MES, Software, Faculty, Student, Appendicitis, Treatment, OTC, MPH, Nursing, Medical school

VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate.

Key Points: 
  • VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate.
  • Treatment gave a third-year non-medical college student the Treatment mobile app and had them join a class of third-year medical school students taking their annual clinical exam.
  • The OSCE exam is a standard exam given at medical, nursing and other professional healthcare schools.
  • They are integral in medical education, as they allow a student to practice and demonstrate clinical diagnostic skills in an artificial medical scenario.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.